AMARIN CORPORATION PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.89 USD | +3.14% |
|
-3.06% | +2.29% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 188M | Sales 2025 * | 228M | Capitalization | 355M |
|---|---|---|---|---|---|
| Net income 2024 * | -75M | Net income 2025 * | -51M | EV / Sales 2024 * | 1.65 x |
| Net cash position 2024 * | 43.92M | Net cash position 2025 * | 159M | EV / Sales 2025 * | 0.86 x |
| P/E ratio 2024 * |
-4.58
x | P/E ratio 2025 * |
-6.7
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.48% |
More Fundamentals
* Assessed data
More news
Latest transcript on Amarin Corporation plc
More recommendations
More press releases
More news
| 1 day | -11.51% | ||
| 1 week | +2.81% | ||
| Current month | -6.30% | ||
| 1 month | -19.36% | ||
| 3 months | -29.85% | ||
| 6 months | +14.17% | ||
| Current year | -0.82% |
1 week
0.86
1.03
1 month
0.811.05
Current year
0.801.37
1 year
0.651.49
3 years
0.655.97
5 years
0.6526.12
10 years
0.6526.12
| Managers | Title | Age | Since |
|---|---|---|---|
Patrick Holt
CEO | Chief Executive Officer | 52 | 23-07-17 |
Thomas Reilly
DFI | Director of Finance/CFO | 52 | 22-06-19 |
| Compliance Officer | 55 | Nov. 14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Louis Sterling
BRD | Director/Board Member | 45 | 23-02-27 |
Odysseas Kostas
CHM | Chairman | 49 | 23-02-27 |
Keith Horn
BRD | Director/Board Member | 66 | 23-02-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 0.8899 | +3.13% | 419 178 |
| 24-05-08 | 0.8629 | -11.51% | 1,905,937 |
| 24-05-07 | 0.9751 | -0.50% | 648,108 |
| 24-05-06 | 0.98 | +7.69% | 1,661,978 |
| 24-05-03 | 0.91 | -0.87% | 464,012 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotes
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
0.8629
USD
Average target price
1
USD
Spread / Average Target
+15.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.82% | 355M | |
| +2.93% | 108B | |
| -3.55% | 23.46B | |
| -14.60% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -8.83% | 17.19B | |
| +5.51% | 13.99B | |
| +37.49% | 12.53B | |
| +329.39% | 8.81B |
- Stock Market
- Equities
- AMRN Stock